Zwany M.
- Country
- The Netherlands
- Department
- #1401: Neurology
Research Overview
- A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
- Long-Term Safety Assessment of Fenfluramine Hydrochloride as Adjunctive Therapy in Patients with Dravet or Lennox-Gastaut Syndrome
- Efficacy and Safety of Fenfluramine Hydrochloride in Pediatric and Adult Patients with CDKL5 Deficiency Disorder: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 6 of 51 partner sites.
Specializations
Rare Epileptic Disorders
This investigator specializes in treating severe forms of epileptic encephalopathies, with particular expertise in managing rare seizure disorders that typically begin in childhood.
- Dravet Syndrome
- Lennox-Gastaut Syndrome
- CDKL5 Deficiency Disorder
Their research encompasses novel therapeutic approaches for managing treatment-resistant seizures in these rare conditions.
Treatment Innovation
The investigator focuses on evaluating innovative therapeutic interventions for rare epileptic disorders, including both established and experimental treatments.
- Adjunctive Therapies
- Long-term Safety Assessment
- Novel Anticonvulsant Medications
Their work includes investigating combinations of standard-of-care treatments with new therapeutic options.
Clinical Management
The investigator's expertise extends to comprehensive seizure management strategies incorporating multiple therapeutic approaches.
- Antiseizure Medications
- Vagus Nerve Stimulation
- Dietary Interventions
Their research explores integrated treatment approaches for complex epileptic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.